CN-121628833-B - Human ampulla cancer cell line DPC-X5 and application thereof

Abstract

A human ampulla cancer cell line DPC-X5 and application thereof, belonging to the field of microbial animal cell lines. The human ampulla cancer cell line is named as human ampulla cancer cell line (homo sapiens) DPC-X5, and is preserved in China Center for Type Culture Collection (CCTCC) in the 10 th month of 2025, wherein the preservation number is CCTCC NO: C202580. The humanized ampulla cancer cell line DPC-X5 can be applied to the establishment of a cell model for the generation, development or metastasis of ampulla cancer. The humanized ampulla cancer cell line DPC-X5 can be applied to the research of the differentiation mechanism, the cell morphology and function abnormality of ampulla cancer and the tumor infiltration and metastasis mechanism of the ampulla cancer and the cell model for guiding the clinical comprehensive diagnosis and treatment. The human-derived ampulla cancer cell line DPC-X5 can be applied to researching the generation mechanism of ampulla cancer and screening medicines for preventing and treating ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to the establishment of an ampulla cancer animal model.

Inventors

• XU HAO
• MIAO XIN
• SU YUANHUI
• YU CHENG
• HUANG WEI

Assignees

• 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院）

Dates

Publication Date

20260508

Application Date

20260203

Claims (5)

1. 1. The human ampulla cancer cell line is named as human ampulla cancer cell line (homo sapiens) DPC-X5 and is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of C202580 at 10 and 30 of 2025.
2. 2. Use of a human-derived ampulla cancer cell line according to claim 1 for the establishment of a cell model for ampulla carcinogenesis, development or metastasis.
3. 3. The use of the human-derived ampulla cancer cell line according to claim 1 for studying the differentiation mechanism, cell morphology and dysfunction, tumor infiltration and metastasis mechanism of ampulla cancer and for guiding the clinical comprehensive diagnosis and treatment of a cell model.
4. 4. The use of the human-derived ampulla cancer cell line according to claim 1 for studying the generation mechanism of ampulla cancer and screening medicines for preventing and treating ampulla cancer.
5. 5. Use of the human-derived ampulla cancer cell line according to claim 1 for the establishment of an ampulla cancer animal model.

Description

Human ampulla cancer cell line DPC-X5 and application thereof Technical Field The invention belongs to the technical field of microbial animal cell lines, and particularly relates to a humanized ampulla cancer cell line DPC-X5 and application thereof. Background Ampulla cancer is a relatively rare tumor that accounts for 0.2% of gastrointestinal cancers, but accounts for 20% of all cancers around the ampulla. Ampulla cancer can occur at any age, but is more common between 60 and 65 years old, with a ratio of about 3:2 for men and women. The symptoms of biliary tract obstruction appear early, the surgical excision rate of ampulla cancer is far higher than that of other ampulla peripheral malignant tumors, and the prognosis is better. According to morphological and immunohistochemical characteristics, the ampullate cancer is divided into intestinal ampullate cancer, pancreatic-biliary ampullate cancer and mixed ampullate cancer. Because of the rare occurrence of tumors, clinical trials are lacking, standardized adjuvant treatment regimens for ampulla cancer remain to be established. The tumor cell line can reflect the characteristics of the tumor to a certain extent, and is the most widely applied model in tumor research. Tumor cell lines greatly facilitate understanding of tumor biology and development of antitumor drugs. A complete tumor cell line bank should reflect the diversity of tumor phenotypes and be able to provide cell lines of different tumor heterogeneity, while the constant creation of new cell lines of different backgrounds has significant scientific value due to the existence of ethnicity and regional differences. However, no chinese-derived ampulla cancer cell line has been reported to date. Therefore, it is necessary to establish a Chinese-derived ampulla cancer cell line. Disclosure of Invention The invention aims to provide a novel humanized ampulla cancer cell line DPC-X5 and application thereof, aiming at the defect of lacking an ampulla cancer cell line in the prior art. The cell line can be used for basic research of ampulla cancer, drug screening, animal model construction and the like. The invention provides a humanized ampulla cancer cell line named as humanized ampulla cancer cell line (homo sapiens) DPC-X5, wherein the preservation number is CCTCC NO: C202580. The human-derived ampulla cancer cell line DPC-X5 can be used as a cell model for the research of the generation, development or metastasis mechanism of ampulla cancer. The human ampulla cancer cell line DPC-X5 can also be used to create an animal model of ampulla cancer. The invention adopts a surgical excision specimen from a 50-year-old female, and adopts a mixed digestion of type II collagenase and neutral proteinase to perform primary culture, and a ampulla cancer cell line is established by cell culture technology, and is named as a humanized ampulla cancer cell line (homo sapiens) DPC-X5. The rice has been preserved in 2025 and 10 months 30 days, and the preservation unit is China center for type culture Collection (CCTCC for short), the preservation center address is China university of Wuhan, and the preservation number is CCTCC NO: C202580. The cell strain has the following biological characteristics: 1. the cell grows by adherence, is inhibited in a non-contact way, and can generate superposition growth phenomenon. 2. The cell doubling time was 85h. 3. The result of cell immunohistochemistry shows that DPC-X5 is a medium-low differentiation ampulla cancer cell line. 4. Chromosome analysis suggests that 70% of DPC-X5 cells are sub-3 ploidy karyotypes and 30% are sub-tetraploid karyotypes, with complex chromosome number and structural aberrations, representative karyotypes being 60, XXX der (5), der (8), der (9), and der (21). 5. DPC-X5 cells are resistant to gemcitabine, oxaliplatin, paclitaxel and 5-FU. 6. DPC-X5 can quickly form subcutaneous transplanted tumor after being inoculated into NXG mice, and the tumor forming rate is 100 percent. 7. The humanized ampulla cancer cell line DPC-X5 can be used as a cell model for researching the differentiation mechanism, cell morphology and function abnormality, tumor infiltration and metastasis mechanism of ampulla cancer, guiding clinical comprehensive diagnosis and treatment and the like. The humanized ampulla cancer cell line DPC-X5 can be applied to establishment of a cell model of ampulla cancer occurrence, development or metastasis. The humanized ampulla cancer cell line DPC-X5 can be applied to research on differentiation mechanism, cell morphology and function abnormality of ampulla cancer, tumor infiltration and metastasis mechanism and cell model for guiding clinical comprehensive diagnosis and treatment. The humanized ampulla cancer cell line DPC-X5 can be applied to researching the generation mechanism of ampulla cancer and screening medicines for preventing and treating ampulla cancer. The ampulla cancer cell line DPC-X5 can be applied to the establishment of